Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib PK and Safety in Chinese Patients with Relapsed iNHL
NCT03498430Phase 1Completed
- Sponsor
- Bayer
- Start
- Apr 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of copanlisib in Indolent Non-Hodgkin Lymphoma (INHL), sponsored by Bayer. Primary endpoints: Maximum Plasma Concentration (Cmax) of Copanlisib and Area Under the Curve (AUC) of Copanlisib. Started Apr 2018; status: completed.
02
Drugs
copanlisib
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT03498430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03498430.